Agendia’s MammaPrint® Breast Cancer Risk-of-Recurrence Test Obtains Favorable Final Payment Determination from CMS for New, Unique Category 1 CPT Code
By a
CMS' Final Determination establishes an increased allowable amount with no patient out-of-pocket responsibility, and thereby enables continued access to Medicare/Medicaid beneficiaries.
CPT code 81521 covers Oncology (breast), mRNA, microarray gene expression profiling of 70 content genes and 465 housekeeping genes, utilizing fresh frozen or formalin-fixed paraffin-embedded tissue, algorithm reported as index related to risk of distant metastases.
"So far this year, we have seen the clinical utility of our test and the Level 1A clinical evidence that supports it recognized by two major
Breast cancer is the most common cancer for women in the
In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology.
For more information on Agendia or the MammaPrint and BluePrint tests, you can visit Agendia's patient site at www.KnowYourBreastCancer.com or the corporate site at www.agendia.com.
Keywords for this news article include: Agendia, Genetics, Oncology, Cancer Risk, Breast Cancer, Health Policy,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC
Lawrence Summers: GOP tax plan will cause thousands of deaths
Many Travelers Purchasing Peace of Mind with Travel Insurance According to GO Group Survey
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News